---
title: "SSY Group wins China NMPA approval for vitamin K1 injection product"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296431792.md"
description: "SSY Group has obtained China NMPA production registration approval for its vitamin K1 injection (1 ml: 10 mg). Classified as a Category 3 chemical drug, this product is treated as having passed the consistency evaluation. This approval expands SSY Group's portfolio of injectable drugs."
datetime: "2026-08-20T04:00:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296431792.md)
  - [en](https://longbridge.com/en/news/296431792.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296431792.md)
generator: "portal-rs"
---

# SSY Group wins China NMPA approval for vitamin K1 injection product

-   SSY Group received China NMPA production registration approval for vitamin K1 injection (1 ml: 10 mg). \* Classed as a Category 3 chemical drug, treated as having passed consistency evaluation. \* Approval expands the group’s injectable drugs portfolio. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SSY Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260820-12291962), on August 20, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [02005.HK](https://longbridge.com/en/quote/02005.HK.md)
- [00388.HK](https://longbridge.com/en/quote/00388.HK.md)
- [80388.HK](https://longbridge.com/en/quote/80388.HK.md)
- [HKXCY.US](https://longbridge.com/en/quote/HKXCY.US.md)

## Related News & Research

- [SSY Group says China NMPA clears generic consistency review for diltiazem tablets 30 mg](https://longbridge.com/en/news/297758026.md)
- [SSY Group wins China NMPA approval for ozagrel sodium injection](https://longbridge.com/en/news/296882931.md)
- [SSY Group Expands Restricted Share Award Scheme with Market Buyback](https://longbridge.com/en/news/297630461.md)
- [Huatai Securities Sticks to Their Buy Rating for SSY Group (LJUIF)](https://longbridge.com/en/news/297389381.md)
- [Promise Launches Clinician-Guided BPC-157 Evaluation as FDA Panel Backs 503A Bulks List Addition](https://longbridge.com/en/news/298349678.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**